Rekombinanter SATB2 Antikörper (AA 150-350)

Produktnummer ABIN7870944

Der Kaninchen Monoklonal anti-SATB2 Antikörper wird verwendet zum Nachweis von SATB2 in Proben von Human. Er wurde validiert für WB und IHC (p).

Kurzübersicht für Rekombinanter SATB2 Antikörper (AA 150-350) (ABIN7870944)

Target: SATB2 (SATB Homeobox 2 (SATB2))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser SATB2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: SATB2-8264R

Produktdetails anti-SATB2 Antikörper

Bindungsspezifität: AA 150-350

Verwendungszweck: SATB2 Antibody (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: A recombinant partial protein sequence (within amino acids 150-350) from the human protein was used as the immunogen for the SATB2 antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the SATB2 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the SATB2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu SATB2

Target: SATB2 (SATB Homeobox 2 (SATB2))

Andere Bezeichnung: SATB2

Hintergrund: SATB2 is a DNA binding protein that specifically binds nuclear matrix attachment regions. It is involved in transcription regulation and chromatin remodeling. SATB2 expression in colorectal carcinomas (CRC) is correlated with good prognosis and in laryngeal squamous cell carcinoma it functions as a tumor suppressor wherein loss of expression is positively correlated with high tumor grade and recurrence. Moreover, SATB2, in combination with CK20, could identify almost all CRC s. Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2, and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive for SATB2. Additionally, SATB2 antibody can identify neuroendocrine neoplasms of colon and rectum because SATB2 is usually negative in neuroendocrine neoplasms of the GI tract, pancreas, and lung. More recently, it has been reported that SATB2 is a sensitive marker for tumors with osteoblastic differentiation.

UniProt: Q9UPW6